Cue Biopharma (CUE) EV/EBITDA: History & Chart

Cue Biopharma, Inc.(CUE)

Biotechnology · Boston, MA

$23.94-0.42 (-1.73%)

Delayed quote: Oct 6, 2026, 10:55 AM EDT

About Cue Biopharma, Inc.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.

Boston, MA

29 employees

www.cuebiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Shao-Lee Lin

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Cue Biopharma, Inc. (CUE)	$173.89M	N/A	N/A	N/A	N/A
MediWound Ltd. (MDWD)vs ›	$172.77M	N/A	7.02x	7.02x	7.02x
Precision BioSciences, Inc. (DTIL)vs ›	$172.18M	N/A	N/A	N/A	N/A
Nkarta, Inc. (NKTX)vs ›	$172.07M	N/A	N/A	N/A	N/A
Compass Therapeutics, Inc. (CMPX)vs ›	$177.78M	N/A	N/A	N/A	N/A
OptimizeRx Corp. (OPRX)vs ›	$169.41M	10.67x	86.42x	168.75x	173.55x
Journey Medical Corporation (DERM)vs ›	$179.09M	141.83x	155.63x	70.41x	70.41x
Organogenesis Holdings Inc. (ORGO)vs ›	$168.56M	212.59x	57.51x	54.12x	36.92x
Canton Strategic Holdings Inc (CNTN)vs ›	$180.85M	N/A	N/A	N/A	N/A
Coherus Oncology, Inc. (CHRS)vs ›	$165.32M	N/A	8.39x	66.32x	66.32x

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Cue Biopharma, Inc. (CUE)

$173.89M

N/A

MediWound Ltd. (MDWD)vs ›

$172.77M

N/A

7.02x

Precision BioSciences, Inc. (DTIL)vs ›